Amarin Corp Plc (AMRN)

[Jt0082]

Per Symphony Health, TRx and NRx Count for Vascepa has grown meaningfully
since pre-REDUCE-IT levels (see chart). Data is updated as of 12/14/18.
n The latest full week script data represents an overall increase in TRx and NRx
values for Vascepa since positive data at AHA on 11/10/2018, but slightly lower
from the previous week.
n This is a YoY TRx and NRx increase of 30.0% and 43.2% respectively, compared
to 12/15/2017 values and WoW TRx and NRx decrease of -1.8% and -3.2%
respectively, compared to 12/7/2018 values.
n It should be noted that weekly results are often variable and particularly true
around holidays. However, there seems to be an overall positive sentiment from
physicians evidenced by numbers continuing to grow over prior year results.
n AMRN remains on track to submit a sNDA to expand its labeling for REDUCE-IT
in early 2019, with approval expected in late 2019.

THANKS as ever Sam.